Additional file 1: of Killer-cell Immunoglobulin-like Receptor (KIR) gene profiles modify HIV disease course, not HIV acquisition in South African women

Statistical Analysis plan: KIR/HLA and viral control in seroconverters in CAPRISA 004 and CAPRISA050/051/HEPS. (DOCX 23 kb

Additional file 4: Figure S3. of Killer-cell Immunoglobulin-like Receptor (KIR) gene profiles modify HIV disease course, not HIV acquisition in South African women

Viral load measures according to HLA-types. . Each panel shows individual viral load or CD4+ T-cell count measures (dots) and LOWESS smoothed curve coloured according to HLA classification as protective, harmful or reference according to previous studies, with 95 % CI shown in grey shading. (PDF 1148 kb

Additional file 6: Figure S4. of Killer-cell Immunoglobulin-like Receptor (KIR) gene profiles modify HIV disease course, not HIV acquisition in South African women

Viral load (A-C) and CD4+ T-cell count (D-F) measures in KIR2DL2/KIR2DL2 (A, D), KIR2DL2/KIR2DL3 (B, E), KIR2DL3/KIR2DL3 (C, F) according to HLA-C1/HLA-C2 ligand grouping. Each panel shows individual viral load or CD4+ T-cell count measures (dots) and LOWESS smoothed curve coloured according to donor HLA C1/C2 allele groupings. (PDF 1822 kb

Additional file 3: Figure S2. of Killer-cell Immunoglobulin-like Receptor (KIR) gene profiles modify HIV disease course, not HIV acquisition in South African women

Cross-sectional viral load measures according to KIR haplotype. Boxes denote interquartile range (box margin) and median (solid line), and whiskers denote range. (PDF 1210 kb

ARIA 2016: Care pathways implementing emerging technologies for predictive medicine in rhinitis and asthma across the life cycle.

The Allergic Rhinitis and its Impact on Asthma (ARIA) initiative commenced during a World Health Organization workshop in 1999. The initial goals were (1) to propose a new allergic rhinitis classification, (2) to promote the concept of multi-morbidity in asthma and rhinitis and (3) to develop guidelines with all stakeholders that could be used globally for all countries and populations. ARIA-disseminated and implemented in over 70 countries globally-is now focusing on the implementation of emerging technologies for individualized and predictive medicine. MASK [MACVIA (Contre les Maladies Chroniques pour un Vieillissement Actif)-ARIA Sentinel NetworK] uses mobile technology to develop care pathways for the management of rhinitis and asthma by a multi-disciplinary group and by patients themselves. An app (Android and iOS) is available in 20 countries and 15 languages. It uses a visual analogue scale to assess symptom control and work productivity as well as a clinical decision support system. It is associated with an inter-operable tablet for physicians and other health care professionals. The scaling up strategy uses the recommendations of the European Innovation Partnership on Active and Healthy Ageing. The aim of the novel ARIA approach is to provide an active and healthy life to rhinitis sufferers, whatever their age, sex or socio-economic status, in order to reduce health and social inequalities incurred by the disease